A Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma Who Have Previously Undergone or Are Not Candidates for Additional Surgery or Radiation.

Trial Profile

A Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma Who Have Previously Undergone or Are Not Candidates for Additional Surgery or Radiation.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2014

At a glance

  • Drugs Pasireotide (Primary)
  • Indications Meningioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 19 Oct 2012 Planned end date changed from 1 Sep 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 13 Dec 2011 Planned End Date changed from 1 Nov 2011 to 1 Sep 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top